Skip to content

Treatment of Withdrawal Symptoms With NADA Acupuncture in Chronic Pain Patients

Unknown statusPhase 4NCT03397212
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

This project aims at examining the following hypotheses: * Treatment with NADA and clonidine reduces intensity of withdrawal symptoms to a greater extent than treatment with clonidine. * Opioid withdrawal improves pain, physical and mental functioning and reduces opioid consumption 3 months and 1 year after withdrawal.

Study details

Official title
Assessment of NADA Acupuncture for Treatment of Withdrawal Symptoms During Gradual Opioid Withdrawal in Chronic Pain Patients
Conditions
Interventions
  • Other: NADA acupuncture
  • Other: Sham acupuncture
Sponsor
Copenhagen University Hospital, Rigshospitalet
Start date
2018-01-15
Primary completion
2022-01-15
Sex
All
Age range
from 18 Years
Results posted
No results posted in this snapshot
Countries
Denmark
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic pain patients treated with opioids over 3 months * The patient's doctor or nurse assesses that there is an indication to opioid withdrawal and / or the patient wishes to withdraw. * The patient is motivated for opioid withdrawal * The patient has experienced withdrawal symptoms * The patient must be able to understand, speak and write Danish * The patient must be able to transport himself to the pain center Exclusion Criteria: * Children under 18 years old * External ear infection * Treatment with benzodiazepines. * Active substance abuse and alcohol abuse. * Contraindications for treatment with clonidine: * Allergy * Bradyarrhythmias caused by diseased sinus cube or AV block of 2nd or 3rd grade. * lactose intolerance * Heart failure * High medullary damage * Cardiac conduction disturbances * Pregnancy and breastfeeding

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03397212